
Hosted by The Uromigos · EN

Jorge Garcia joins us to discuss the process of selecting abstracts for oral presentation and select highlights from this session.

Toni Choueiri discusses this combination cohort of HIF inhibition plus VEGF-R inhibition.

Matt Galsky discusses the ASCO 2025 data regarding ctDNA from the NIAGARA neoadjuvant chemo +/- durvalumab study.

Jeannie Hoffman-Censits discusses her randomized phase 2 adding SG to maintenence avelumab in mUC.

Michiel Van Der Heijden joins us to discuss the Ipi/Nivo vs chemo randomization in this trial from his ASCO 2025 presentation

Monty Pal discusses more correlates from this trial including matched baseline and progression tissue samples.

David McDermott joins us on the heels of his outstanding discussion of the clinical science symposium on RCC biomarkers.

Practice Changing? 独断と偏見で選んだ注目演題について結果の予想も含めて議論しました。

Silke, Tom and Brian discuss what they are looking forward to at ASCO 2025

日本と海外の違いはあるのか?mHSPCとmCRPCのUromigos Scoreについて激論!!